Iron chelation as therapy for HIV and Mycobacterium tuberculosis co-infection under conditions of iron overload

Current Pharmaceutical Design

Volumn 12, Issue 16, 2006, Pages 1943-1947

  Meyer, Debra ^a  

^a UNIVERSITY OF JOHANNESBURG   (South Africa)

Author keywords

Desferrioxamine; HIV 1 core protein; Host defense; Iron chelators; Tuberculosis

Indexed keywords

BLEOMYCIN; DEFERIPRONE; DEFEROXAMINE; IRON CHELATING AGENT; RIBONUCLEOTIDE REDUCTASE; SURFACTANT PROTEIN A;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADJUVANT THERAPY; ANTIBACTERIAL ACTIVITY; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG ABSORPTION; DRUG STRUCTURE; ENZYME INACTIVATION; FEASIBILITY STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IRON CHELATION; IRON OVERLOAD; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS; VIRUS INHIBITION; VIRUS REPLICATION;

HIV; HIV INFECTIONS; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; MACROPHAGES; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 33744766196     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206777442164     Document Type: Review

References (49)

1. Biswas P, Ferrarini M, Mantelli B, Fortis C, Poli G, Lazzarin A, et al. Double-edged effect of Vgamma9/Vdelta2 T lymphocytes on viral expression in an in vitro model of HIV-1/mycobacteria co-infection. Eur J Immunol 2003; 33: 252-63.
2. Goletti D, Weissman D, Jackson RW, Graham NM, Vlahov D, Klein RS, et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol 1996; 157: 1271-8.
3. Chaisson RE, Schecter GF, Theuer CP, Rutherford GW, Echenberg DF, Hopewell PC. Tuberculosis in patients with the acquired immunodeficiency syndrome: clinical features, responses to therapy and survival. Am Rev Respir Dis 1987, 136: 570-4.
4. Toossi Z, Mayanja-Kizza H, Hirsch CS, Edmonds KL, Spahlinger T, Hom DL, et al. Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients. Chn Exp Immunol 2001; 123: 233-8.
5. Collins F. Mycobacterial disease, immunosuppression, and acquired immunodeficiency syndrome. Clin Microbiol Rev 1989; 2: 360-77.
6. Lounis N, Truffort-Pernot C, Grosset J, Gordeuk VR, Boelaert JR. Iron and Mycobacterium tuberculosis infection. J Clin Virol 2001; 20(3): 123-6.
7. Gordeuk VR, Delanghe JR, Langlois MR, Boelaert JR. Iron status and the outcome of HIV infection: an overview. J Clin Virol 2001; 20: 111-5.
8. Georgiou. NA, Van der Bruggen T, Oudshoorn M, Nottet HS, Marx JJ, Van Asbeck BS. Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin. J Infect Dis 2000; 181(2): 484-90.
9. Weinberg ED. Iron withholding: a defense against viral infections. Biometals 1996; 9: 393-9.
10. Juffermans NP, Paxton WA, Dekkers PE, Verbon A, de Jonge E, Speelman P, et al. Up-regulation of HIV coreceptors CXCR4 and CCR5 on CD4(+) T cells during human endotoxemia and after stimulation with (myco)bacterial antigens: the role of cytokines. Blood 2000; 96: 2649-54.
11. Pedral-Sampaio D, Alves CR, Netto EM, Brites C, Oliviera AS, Badaro R. Efficacy and safety of Efavirenz in HIV patients on Rifampin for tuberculosis. Braz J Infect Dis 2004; 8: 211-6.
12. Marx JJ. Iron and infection: competition between host and microbes for a precious element. Best Pract Res Clin Haematol 2002; 15: 411-26.
13. Means RT, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992; 80: 1639-47.
14. Weiss G, Fuchs D, Hausen A, Reibnegger G, Werner ER, Werner-Felmayer G, et al. Iron modulates interferon-gamma effects in the human myelomonocytic cell line THP-1. Exp Hematol 1992; 20: 605-10.
15. Crichton RR, Ward RJ. An overview of iron metabolism: molecular and cellular criteria for the selection of iron chelators. Curr Med Chem 2003; 10: 997-1004.
16. Tam TF, Leung-Toung R, Li W, Wang Y, Karimian K, Spino M. Iron chelator research: past, present; and future. Curr Med Chem 2003; 10: 983-95.
17. Harrison SA, Bacon BR. Hereditary hemochromatosis: update for 2003. J Hepatol 2003; 38: S14-S23.
18. Moyo VM, Gangaidzo IT, Gordeuk VR, Kiire CF, Macphail AP. Tuberculosis and iron overload in Africa: a review. Cent Afr J Med 1997; 43(11): 334-9.
19. Gordeuk VR. African iron overload. Semin Hematol 2002: 39: 263-9.
20. Barton JC, Acton RT, Rivers CA, Bertoli LF, Gelbart T, West C, et al. Genotypic and phenotypic heterogeneity of African Americans with primary iron overload. Blood Cells Mol Dis 2003, 31: 310-19.
21. Beutler E, Barton JC, Felitti VJ, Gelbart T, West C, Lee PL, et al. Ferroportin 1 (SCL40A1) variant associated with iron overload in African-Americans. Blood Cells Mol Dis 2003; 31: 305-9.
22. Hershko C. Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators. Baillieres Clin Haematol 1994; 7(4): 965-1000.
23. Georgiou NA, Van der Bruggen T, Oudshoorn M, Hider RC, Marx JJ, Van Asbeck BS. Human immunodeficiency virus type 1 replication inhibition by the bidentate iron chelators CP502 and CP511 is caused by proliferation inhibition and the onset of apoptosis. Eur J Clin Invest 2002; 32(l): 91-6.
24. Van Asbeck BS, Georgiou NA, Van der Bruggen T, Oudshoorn M, Nottet HS, Marx JJ. Anti-HIV effect of iron chelators: different mechanisms involved. J Clin Virol 2001; 20: 141-7.
25. Hodges YK, Antholine WE, Horwitz LD. Effect on ribonucleotide reductase of novel lipophilic iron chelators: the desferri-exochelins. Biochem Biophys Res Commun 2004; 315(3): 595-8.
26. Hider RC, Choudhury R, Rai BL, Dehkordi LS, Singh S. Design of orally active iron chelators. Acta Haematol 1996; 95: 6-12.
27. Cragg L, Hebbel RP, Miller W, Solovey A, Selby S, Enright H. The iron chelator L1 potentiates oxidative DNA damage in iron-loaded liver cells. Blood 1998; 92(2): 632-8.
28. Traore HN, Meyer D. Comparing qualitative and quantitative spectroscopic techniques for the detection of the effect of direct iron loading of mammalian cell cultures. Methods Cell Sci 2002; 23: 175-84.
29. Traore HN, Meyer D. The effect of iron overload on in vitro HIV-1 infection. J Clin Virol 2004; 31S: S92-S98
30. Bornman L, Baladi S, Richard MJ, Tyrell RM, Polls BS. Differential regulation and expression of stress proteins and ferritin in human monocytes. J Cell Physiol 1999; 178: 1-8.
31. Meylan PR, Munis JR, Richman DD, Kornbluth RS. Concurrent human immunodeficiency virus and mycobacterial infection of macrophages in vitro does not reveal any reciprocal effect. J Infect Dis 1992; 165: 80-6.
32. Gold JA, Hoshino Y, Tanaka N, Rom WN, Raju B, Condos R, et al. Surfactant protein A modulates the inflammatory response in macrophages during tuberculosis. Infect Immun 2004; 72(2): 645-50.
33. Collins L, Franzblau SG. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother 1997; 41: 1004-9.
34. Traore HN, Meyer D. In vitro effect of iron overload on both host viability and pathogen multiplication during co-infection of HIV and Mycobacterium tuberculosis. 2005; manuscript in preparation.
35. Gobin J, Wong DK, Gibson BW, Horwitz MA. Characterization of exochelins of the Mycobacterium bovis type strain and BCG substrains. Infect Immun 1999; 67(4): 2035-9.
36. Gobin J, Horwitz MA. Exochelins of Mycobacterium tuberculosis remove iron from human iron-binding proteins and donate iron to mycobactins in the M. tuberculosis cell wall. J Exp Med 1996; 183(4): 1527-32.
37. Gobin J, Moore CH, Reeve JR, Wong DK, Gibson BW, Horwitz MA. Iron acquisition by Mycobacterium tuberculosis: isolation and characterization of a family of iron-binding exochelins. Proc Natl Acad Sci USA 1995; 92(11): 5189-93.
38. Ward CG. Iron and immunologic function. J Burn Care Rehabil 1987; 8(6): 487-91.
39. Cronje L, Edmondson N, Eisenach DK, Bornman L. Iron and iron chelating agents modulate Mycobacterium tuberculosis growth and the monocyte-macrophage viability and effector functions. FEMS Immuno Med Micro 2005, in press.
40. Endo K. Drug activity of bleomycin against tubercle bacilli isolated from pulmonary tuberculosis in patients. Jpn J Antibiot 1973; 26 (6): 501-3.
41. Ertem E, Yuce K, Karakartal G, Onal O, Yuce G. The antituberculous effect of bleomycin. J Antimicrob Chemother 1990; 26(6): 862-3.
42. Douvas GS, May MH, Kolnagou A, Kontoghiorghes GJ. Effects on Mycobacterium avium replication in normal human macrophages by deferiprone (L1) and other iron chelators. Possible implications on toxicity. Arzneimittelforschung 2002; 52(1): 45-52.
43. Cronje L, Bornman L. Iron overload and tuberculosis: a case for iron chelation therapy. Int J Tuberc Lung Dis 2005; 9(1): 2-9.
44. Ratledge C. Iron, mycobacteria and tuberculosis. Tuberculosis (Edinb) 2004; 84: 110-30.
45. Comis RL. Bleomycin pulmonary toxicity: current status and future directions. Semin Oncol 1992; 19 (Suppl 5): 64-70.
46. Budihna M, Soba E, Smid L, Zakotnik B, Strojan P, Cemazar M, et al. Inoperable oropharyngeal carcinoma treated with concomitant irradiation, mitomycin C and bleomycin - long term results. Neoplas 2005; 52(2): 165-74.
47. Duncan K. Identification and validation of novel drug targets in tuberculosis. Curr Pharm Des 2004; 10(26): 3185-94.
48. Kantardjieff K, Rupp B. Structural bioinformatic approaches to the discovery of new antimycobacterial drugs. Curr Pharm Des 2004; 10(26): 3195-211.
49. Mitchison DA, Coates AR. Predictive in vitro models of the sterilizing activity of anti-tuberculosis drugs. Curr Pharm Des 2004; 10(26): 3285-95.